LifeVantage Corporation — Form 10-Q Summary
Period clarification: The supplied filing is for the quarter ended March 31, 2024 (LifeVantage fiscal Q3 2024), not 2023 Q3. Quarterly figures compare with the three months ended March 31, 2023; nine-month figures compare with the nine months ended March 31, 2023. Unaudited; amounts below are in millions unless stated otherwise.
Business context and reporting period
LifeVantage sells dietary supplements, personal-care and other wellness products through customers and independent consultants using a commission-based direct-selling model. It operates across the Americas and Asia/Pacific & Europe. Management says results depend significantly on attracting and retaining consultants and customers. Active accounts fell 14.8% year over year to 127,000 at March 31, 2024, including 49,000 active consultants and 78,000 active customers.
Key financial metrics
| Metric | Q3 FY2024 | Q3 FY2023 | Nine months FY2024 | Nine months FY2023 |
|---|---|---|---|---|
| Revenue | $48.2 | $53.7 | $151.2 | $159.2 |
| Gross profit / margin | $38.1 / 78.9% | $43.1 / 80.2% | $119.8 / 79.2% | $126.9 / 79.7% |
| Operating income | $1.9 | $1.6 | $1.4 | $1.7 |
| Net income | $1.7 | $1.0 | $1.6 | $0.6 |
| Diluted EPS | $0.13 | $0.08 | $0.13 | $0.05 |
| Operating cash flow | Not separately provided | Not separately provided | $9.6 | $3.1 |
At March 31, 2024, cash was $17.4, down from $21.6 at June 30, 2023. Working capital was $15.3, versus $24.7. The company reported no outstanding borrowings on its former credit facility at quarter-end. Lease liabilities totaled $13.5, including $1.7 current. Nine-month investing cash use was $2.0, mainly capital expenditures; financing cash use was $11.7, including $6.4 of dividends and $4.6 of share repurchases. Management said cash and expected operating cash flow should cover requirements for at least the next 12 months.
Material changes versus prior comparable periods
- Quarterly revenue declined 10.2%; nine-month revenue declined 5.0%. Quarterly net income increased to $1.7 from $1.0, while nine-month net income increased to $1.6 from $0.6.
- Asia/Pacific & Europe revenue fell 22.4% in the quarter and 16.4% over nine months; Americas revenue declined 5.9% and 0.7%, respectively. Japan quarterly revenue fell 23.5%.
- Management attributed revenue pressure to fewer active accounts, foreign exchange, the prior closure of China e-commerce operations, and comparison with earlier purchasing ahead of price increases in Japan. Foreign exchange reduced revenue by $0.8 in the quarter and $1.3 over nine months.
- Gross margin contracted, which the company attributed to product mix, raw-material and manufacturing costs, shipping, and warehouse fulfillment. Lower commissions as a percentage of revenue partly offset this: 40.9% versus 44.3% in the quarter and 42.3% versus 44.7% year to date.
- SG&A was $16.4 in the quarter and $54.5 year to date. Year-to-date SG&A increased slightly, with proxy-contest expenses partly offset by lower event, compensation, lease, and professional-services costs.
- Operating cash flow improved year over year, but cash declined as shareholder distributions and repurchases exceeded operating and investing cash flows. The company repurchased $4.6 of shares during the nine months and paid a one-time $0.40-per-share dividend in addition to quarterly dividends.
Outlook, risks, contingencies, and unusual items
- No specific revenue or earnings guidance is provided. Management expects recent product launches, including TrueScience skin-care products and Liquid Collagen, to support average order size and customer and consultant attraction; it also says account declines and international market challenges remain important.
- The former $5.0 revolving facility matured and terminated on March 31, 2024. After quarter-end, on April 12, the company entered into a new secured $5.0 revolving credit facility, bearing interest at Term SOFR (with a 0% floor) plus 2.0%, maturing April 12, 2027. No borrowings had been made as of the report date; the agreement includes financial tests, covenants, and default provisions.
- The company reported no probable loss contingencies requiring accrual or disclosure. It noted that litigation and regulatory matters can be unpredictable and that unfavorable outcomes or publicity could affect results. Proxy-contest-related expenses were identified as a current-period cost driver.
- A stockholder rights plan, adopted in August 2023, is scheduled to expire August 24, 2024 unless earlier terminated, redeemed, or exchanged. It generally becomes exercisable following acquisition of 12% of common stock (20% for certain passive investors).
- Other stated risks include consultant and customer retention, product acceptance, direct-selling and product regulation, foreign exchange, supply and inventory management, cyber and IT disruption, tax matters, and compliance with credit-facility covenants.
Important facts for investors to verify
- Confirm the requested period: this filing covers fiscal Q3 2024, not 2023 Q3.
- Track active consultant and customer counts, revenue trends by geography, and whether new products can offset account attrition.
- Review gross-margin pressure, proxy-contest costs, and the sustainability of improved operating cash flow.
- Assess cash use for dividends and repurchases against liquidity needs, and verify the new facility’s covenants and any subsequent borrowing.
- Monitor the rights plan’s expiration or any changes, and developments in litigation, regulatory matters, and tax estimates.